6 March 2013 -- Vernalis plc and Servier, France's largest privately-owned pharmaceutical company, today
announce the further extension of their ongoing oncology collaboration initiated in May
2007.
This is the first of three collaborations between Vernalis and Servier and focuses on multiple
undisclosed oncology targets. It was initially extended in October 2011 and is now extended
for a further two years.
Ian Garland, CEO of Vernalis, commented “We are delighted by this news which reflects
Servier’s continued endorsement of our joint achievements over the past few years.”
Servier's head of research, Bernard Marchand, said: “this 2-year extension highlights our
commitment to cancer research through innovative drug discovery platforms.”
Vernalis Contacts:
Vernalis Contacts:
Ian Garland, Chief Executive Officer +44 (0) 118 938 0015
David Mackney, Chief Financial Officer
Nomura Code Securities Limited: +44 (0) 20 7776 1200
Juliet Thompson
Jonathan Senior
Brunswick Group: +44 (0) 20 7404 5959
Jon Coles
About Servier
Servier is the leading independent French pharmaceutical company, established in 1954 by its
founder, Jacques Servier, M.D., Pharm.D. The group is established in 140 countries and 90%
of Servier products are prescribed out of France. Sales turnover in 2012 rose to 3.9 billion
euros. Almost 25% of Servier's turnover is invested in Research and Development. The
Servier Group counts 19 International Centers of Therapeutic Research, and its principal
therapeutic research orientations are cardiovascular diseases, diabetes, neuropsychiatric
disorders, cancer, and osteoarticular diseases.
More information is available at: www.servier.com.
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant
expertise in drug development. The Group has one marketed product, frovatriptan for the
acute treatment of migraine, an exclusive licensing agreement to develop and commercialise
multiple novel products focussed on the US prescription cough/cold market as well as seven
programmes in its NCE development pipeline. Vernalis has significant expertise in fragment
and structure based drug discovery which it leverages to enter into collaborations with larger
pharmaceutical companies. The Company’s technologies, capabilities and products are
endorsed by collaborations with Endo, Genentech, Lundbeck, Menarini, Novartis, Servier
and Tris.
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current
expectations regarding future events including the clinical development and regulatory
clearance of the Company's products, the Company's ability to find partners for the
development and commercialisation of its products, as well as the Company's future capital
raising activities. Forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number of factors
including the success of the Company's research strategies, the applicability of the
discoveries made therein, the successful and timely completion of clinical studies, the
uncertainties related to the regulatory process, the ability of the Company to identify and
agree beneficial terms with suitable partners for the commercialisation and/or development
of its products, as well as the achievement of expected synergies from such transactions, the
acceptance of frovatriptan and other products by consumers and medical professionals, the
successful integration of completed mergers and acquisitions and achievement of expected
synergies from such transactions, and the ability of the Company to identify and consummate
suitable strategic and business combination transactions.